Advanced Therapeutics
14 June 2023
Peptide-Decorated Artificial Erythrocyte Microvesicles Endowed with Lymph Node Targeting Function for Drug Delivery
Gan Zhang1,2, Wenjing Cheng1,2, Ni Yang1,2,, Baoye Yang1,2, Shi Yu1,2, Jing Zheng1,2, Miaomiao Li1,2, Yaling Fu1,2, Xinzhi Li1,2, Yinhong Song1,2, Zhihong Zhang3,4 and Xiang Yu1,2,3
1 Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, China Three Gorges University, Yichang, 443002 China
2 Medical College, China Three Gorges University, Yichang, 443002 China
3 School of Biomedical Engineering, Hainan University, Haikou, 570228 China
4 Britton Chance Center for Biomedical Photonics, Wuhan National Laboratory for Optoelectronics-Huazhong University of Science and Technology, Wuhan, 430074 China
† G.Z., W.C., and N.Y. contributed equally to this work.
10.1002/adtp.202200236
In article number 2200236, Zhihong Zhang, Xiang Yu, and co-workers achieve the direct size conversion of erythrocyte-derived MVs (eMVs) via incubation with an ApoA-I mimetic peptide (R4F) capable of binding phospholipids. R4F peptide modification endows eMVs with SR-B1 receptor and lymph node targeting functions, providing an excellent drug delivery system for the targeted treatment of lymph node-associated diseases.
Anhui Province Academy of Science and Technology, No. 128,Wanshui Road, Hi-Tech Zone, Hefei City, Anhui Province, China
+86 17354022649
service@sondii.com
IPv6 network supported
Our hours
Beijing time: 9:00-18:00
